{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:38:02Z","timestamp":1792521482805,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["402442\/2020-2"],"award-info":[{"award-number":["402442\/2020-2"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>To evaluate the disease activity before and after COVID-19 and risk factors associated with outcomes, including hospitalization, intensive care unit (ICU) admission, mechanical ventilation (MV) and death in patients with spondylarthritis (SpA).\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>ReumaCoV Brazil is a multicenter prospective cohort of immune-mediated rheumatic diseases (IMRD) patients with COVID-19 (case group), compared to a control group of IMRD patients without COVID-19. SpA patients enrolled were grouped as axial SpA (axSpA), psoriatic arthritis (PsA) and enteropathic arthritis, according to usual classification criteria.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>353 SpA patients were included, of whom 229 (64.9%) were axSpA, 118 (33.4%) PsA and 6 enteropathic arthritis (1.7%). No significant difference was observed in disease activity before the study inclusion comparing cases and controls, as well no worsening of disease activity after COVID-19. The risk factors associated with hospitalization were age over 60\u00a0years (OR\u2009=\u20093.71; 95% CI 1.62\u20138.47, <jats:italic>p<\/jats:italic>\u2009=\u20090.001); one or more comorbidities (OR\u2009=\u20092.28; 95% CI 1.02\u20135.08, <jats:italic>p<\/jats:italic>\u2009=\u20090.001) and leflunomide treatment (OR\u2009=\u20094.46; 95% CI 1.33\u201324.9, <jats:italic>p<\/jats:italic>\u2009=\u20090.008). Not having comorbidities (OR\u2009=\u20090.11; 95% CI 0.02\u20130.50, <jats:italic>p<\/jats:italic>\u2009=\u20090.001) played a protective role for hospitalization. In multivariate analysis, leflunomide treatment (OR\u2009=\u20098.69; CI\u2009=\u200995% 1.41\u201353.64; <jats:italic>p<\/jats:italic>\u2009=\u20090.023) was associated with hospitalization; teleconsultation (OR\u2009=\u20090.14; CI\u2009=\u200995% 0.03\u20130.71; <jats:italic>p<\/jats:italic>\u2009=\u20090.01) and no comorbidities (OR\u2009=\u20090.14; CI\u2009=\u200995% 0.02\u20130.76; <jats:italic>p<\/jats:italic>\u2009=\u20090.02) remained at final model as protective factor.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our results showed no association between pre-COVID disease activity or that SARS-CoV-2 infection could trigger disease activity in patients with SpA. Teleconsultation and no comorbidities were associated with a lower hospitalization risk. Leflunomide remained significantly associated with higher risk of hospitalization after multiple adjustments.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s42358-022-00268-x","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T05:13:11Z","timestamp":1669180391000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["COVID-19 was not associated or trigger disease activity in spondylarthritis patients: ReumaCoV-Brasil cross-sectional data"],"prefix":"10.1186","volume":"62","author":[{"given":"Claudia Diniz Lopes","family":"Marques","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra L\u00facia Euz\u00e9bio","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cleandro P.","family":"Albuquerque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia Araujo","family":"de Sousa Studart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Ranzolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole Pamplona Bueno","family":"de Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea T.","family":"Dantas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme D.","family":"Mota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo G.","family":"Resende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana O.","family":"Marinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Angelieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danieli","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francinne M.","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Omura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilzio A.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurindo","family":"Rocha Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle E.","family":"Brito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana C.","family":"Fernandino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel A.","family":"Yazbek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana P. G.","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Carlos","family":"Ximenes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Silvia S.","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glaucio Ricardo W.","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00edvia C.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Beatriz S. B.","family":"Freitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana M.","family":"Kakehasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Paula M.","family":"Gomides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgard Torres","family":"Reis Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gecilmara S.","family":"Pileggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilda A.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licia Maria H.","family":"Mota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo M.","family":"Xavier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7901-3124","authenticated-orcid":false,"given":"Marcelo","family":"de Medeiros Pinheiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the ReumaCoV-Brasil Registry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,22]]},"reference":[{"key":"268_CR1","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3899\/jrheum.201541","volume":"48","author":"CDL Marques","year":"2021","unstructured":"Marques CDL. Covid-19 and rheumatic diseases: it is time to better understand this association. J Rheumatol. 2021;48:318\u201320.","journal-title":"J Rheumatol"},{"key":"268_CR2","doi-asserted-by":"publisher","first-page":"e000935","DOI":"10.1136\/rmdopen-2019-000935","volume":"5","author":"B Mehta","year":"2019","unstructured":"Mehta B, Pedro S, Ozen G, Kalil A, Wolfe F, Mikuls T, et al. Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study. RMD Open. 2019;5:e000935.","journal-title":"RMD Open"},{"key":"268_CR3","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1136\/ard.2010.128637","volume":"70","author":"K Au","year":"2011","unstructured":"Au K, Reed G, Curtis JR, Kremer JM, Greenberg JD, Strand V, et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:785\u201391.","journal-title":"Ann Rheum Dis"},{"key":"268_CR4","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1136\/ard.2003.011882","volume":"63","author":"A Martinez","year":"2004","unstructured":"Martinez A, Pacheco-Tena C, Vazquez-Mellado J, Burgos-Vargas R. Relationship between disease activity and infection in patients with spondyloarthropathies. Ann Rheum Dis. 2004;63:1338\u201340.","journal-title":"Ann Rheum Dis"},{"key":"268_CR5","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1136\/gutjnl-2020-321411","volume":"69","author":"C Bezzio","year":"2020","unstructured":"Bezzio C, Saibeni S, Variola A, Allocca M, Massari A, Gerardi V, et al. Outcomes of covid-19 in 79 patients with ibd in Italy: an ig-ibd study. Gut. 2020;69:1213\u20137.","journal-title":"Gut"},{"key":"268_CR6","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","volume":"79","author":"M Gianfrancesco","year":"2020","unstructured":"Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al. Characteristics associated with hospitalisation for covid-19 in people with rheumatic disease: data from the covid-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis. 2020;79:859\u201366.","journal-title":"Ann Rheum Dis"},{"key":"268_CR7","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1136\/annrheumdis-2020-218705","volume":"80","author":"A Ciurea","year":"2021","unstructured":"Ciurea A, Papagiannoulis E, Burki K, von Loga I, Micheroli R, Moller B, et al. Impact of the covid-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss clinical quality management cohort. Ann Rheum Dis. 2021;80:238\u201341.","journal-title":"Ann Rheum Dis"},{"key":"268_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1479-5876-12-77","volume":"12","author":"V Germano","year":"2014","unstructured":"Germano V, Cattaruzza MS, Osborn J, Tarantino A, Di Rosa R, Salemi S, et al. Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with dmards, corticosteroids and tnf-alpha antagonists. J Transl Med. 2014;12:77.","journal-title":"J Transl Med"},{"key":"268_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12916-016-0673-8","volume":"14","author":"JA Singh","year":"2016","unstructured":"Singh JA, Hossain A, Kotb A, Wells G. Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis. BMC Med. 2016;14:137.","journal-title":"BMC Med"},{"key":"268_CR10","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1136\/ard.2008.098822","volume":"69","author":"A Fouque-Aubert","year":"2010","unstructured":"Fouque-Aubert A, Jette-Paulin L, Combescure C, Basch A, Tebib J, Gossec L. Serious infections in patients with ankylosing spondylitis with and without tnf blockers: a systematic review and meta-analysis of randomised placebo-controlled trials. Ann Rheum Dis. 2010;69:1756\u201361.","journal-title":"Ann Rheum Dis"},{"key":"268_CR11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/imm.13242","volume":"161","author":"A Voruganti","year":"2020","unstructured":"Voruganti A, Bowness P. New developments in our understanding of ankylosing spondylitis pathogenesis. Immunology. 2020;161:94\u2013102.","journal-title":"Immunology"},{"key":"268_CR12","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S0140-6736(73)91360-3","volume":"1","author":"DA Brewerton","year":"1973","unstructured":"Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DC, Sturrock RD. Ankylosing spondylitis and hl-a 27. Lancet. 1973;1:904\u20137.","journal-title":"Lancet"},{"key":"268_CR13","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1056\/NEJM197304052881403","volume":"288","author":"L Schlosstein","year":"1973","unstructured":"Schlosstein L, Terasaki PI, Bluestone R, Pearson CM. High association of an hl-a antigen, w27, with ankylosing spondylitis. N Engl J Med. 1973;288:704\u20136.","journal-title":"N Engl J Med"},{"key":"268_CR14","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.autrev.2008.03.013","volume":"7","author":"A Mathieu","year":"2008","unstructured":"Mathieu A, Cauli A, Fiorillo MT, Sorrentino R. Hla-b27 and ankylosing spondylitis geographic distribution as the result of a genetic selection induced by malaria endemic? A review supporting the hypothesis. Autoimmun Rev. 2008;7:398\u2013403.","journal-title":"Autoimmun Rev"},{"key":"268_CR15","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.autrev.2009.01.003","volume":"8","author":"A Mathieu","year":"2009","unstructured":"Mathieu A, Paladini F, Vacca A, Cauli A, Fiorillo MT, Sorrentino R. The interplay between the geographic distribution of hla-b27 alleles and their role in infectious and autoimmune diseases: a unifying hypothesis. Autoimmun Rev. 2009;8:420\u20135.","journal-title":"Autoimmun Rev"},{"key":"268_CR16","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.parint.2013.02.003","volume":"62","author":"KF Rodrigues","year":"2013","unstructured":"Rodrigues KF, Fariaearantes TE, Muccioli C, Neto JL, Pinheiro MM. Incidence of toxoplasma retinochoroiditis in patients with ankylosing spondylitis after using tnf-\u03b1 blockers. Parasitol Int. 2013;62:272\u20135.","journal-title":"Parasitol Int"},{"key":"268_CR17","first-page":"89","volume":"6","author":"D den Uyl","year":"2004","unstructured":"den Uyl D, van der Horst-Bruinsma IE, van Agtmael M. Progression of HIV to AIDS: a protective role for hla-b27? AIDS Rev. 2004;6:89\u201396.","journal-title":"AIDS Rev"},{"key":"268_CR18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1056\/NEJMc2009567","volume":"383","author":"R Haberman","year":"2020","unstructured":"Haberman R, Axelrad J, Chen A, Castillo R, Yan D, Izmirly P, et al. Covid-19 in immune-mediated inflammatory diseases - case series from New York. N Engl J Med. 2020;383:85\u20138.","journal-title":"N Engl J Med"},{"key":"268_CR19","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1136\/annrheumdis-2020-217948","volume":"79","author":"C Sanchez-Piedra","year":"2020","unstructured":"Sanchez-Piedra C, Diaz-Torne C, Manero J, Pego-Reigosa JM, Rua-Figueroa I, Gonzalez-Gay MA, et al. Clinical features and outcomes of covid-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. Ann Rheum Dis. 2020;79:988\u201390.","journal-title":"Ann Rheum Dis"},{"key":"268_CR20","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1136\/annrheumdis-2020-217424","volume":"79","author":"S Monti","year":"2020","unstructured":"Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical course of covid-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis. 2020;79:667\u20138.","journal-title":"Ann Rheum Dis"},{"key":"268_CR21","doi-asserted-by":"publisher","first-page":"e24357","DOI":"10.2196\/24357","volume":"9","author":"C Marques","year":"2020","unstructured":"Marques C, Kakehasi AM, Gomides APM, Paiva EDS, Dos Reis Neto ET, Pileggi GCS, et al. Reumacov Brasil Registry: a Brazilian cohort of patients with immuno-mediated chronic inflammatory diseases infected by sars-cov-2. JMIR Res Protoc. 2020;9:e24357.","journal-title":"JMIR Res Protoc"},{"key":"268_CR22","doi-asserted-by":"publisher","first-page":"e001461","DOI":"10.1136\/rmdopen-2020-001461","volume":"7","author":"CDL Marques","year":"2021","unstructured":"Marques CDL, Kakehasi AM, Pinheiro MM, Mota LMH, Albuquerque CP, Silva CR, et al. High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and covid-19: first results of Reumacov Brasil Registry. RMD Open. 2021;7:e001461.","journal-title":"RMD Open"},{"key":"268_CR23","unstructured":"Brasil. Boletim epidemiol\u00f3gico - doen\u00e7a pelo coronav\u00edrus 2019 - amplia\u00e7\u00e3o da vigil\u00e2ncia, medidas n\u00e3o farmacol\u00f3gicas e descentraliza\u00e7\u00e3o do diagn\u00f3stico laboratorial. In: Sa\u00fade Md, editor. Brasil; 2020."},{"key":"268_CR24","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, et al. The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68:777\u201383.","journal-title":"Ann Rheum Dis"},{"key":"268_CR25","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665\u201373.","journal-title":"Arthritis Rheum"},{"key":"268_CR26","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rheumatol. 1994;21:2286\u201391.","journal-title":"J Rheumatol"},{"key":"268_CR27","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1136\/annrheumdis-2018-213184","volume":"77","author":"PM Machado","year":"2018","unstructured":"Machado PM, Landewe R, Heijde DV. Assessment of SpondyloArthritis international S. Ankylosing spondylitis disease activity score (asdas): 2018 update of the nomenclature for disease activity states. Ann Rheum Dis. 2018;77:1539\u201340.","journal-title":"Ann Rheum Dis"},{"key":"268_CR28","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/ard.2008.102053","volume":"69","author":"LC Coates","year":"2010","unstructured":"Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69:48\u201353.","journal-title":"Ann Rheum Dis"},{"key":"268_CR29","doi-asserted-by":"publisher","first-page":"e001464","DOI":"10.1136\/rmdopen-2020-001464","volume":"7","author":"R Hasseli","year":"2021","unstructured":"Hasseli R, Mueller-Ladner U, Hoyer BF, Krause A, Lorenz HM, Pfeil A, et al. Older age, comorbidity, glucocorticoid use and disease activity are risk factors for covid-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. RMD Open. 2021;7:e001464.","journal-title":"RMD Open"},{"key":"268_CR30","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1136\/annrheumdis-2020-217903","volume":"79","author":"C Salvarani","year":"2020","unstructured":"Salvarani C, Bajocchi G, Mancuso P, Galli E, Muratore F, Boiardi L, et al. Susceptibility and severity of covid-19 in patients treated with bdmards and tsdmards: a population-based study. Ann Rheum Dis. 2020;79:986\u20138.","journal-title":"Ann Rheum Dis"},{"key":"268_CR31","first-page":"159","volume":"60","author":"R Cordtz","year":"2020","unstructured":"Cordtz R, Lindhardsen J, Soussi BG, Vela J, Uhrenholt L, Westermann R, et al. Incidence and severeness of covid-19 hospitalisation in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark. Rheumatology (Oxford). 2020;60:159\u201367.","journal-title":"Rheumatology (Oxford)"},{"key":"268_CR32","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/art.21568","volume":"54","author":"F Wolfe","year":"2006","unstructured":"Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 2006;54:628\u201334.","journal-title":"Arthritis Rheum"},{"key":"268_CR33","doi-asserted-by":"publisher","first-page":"111681","DOI":"10.1016\/j.ejmech.2019.111681","volume":"183","author":"D Boschi","year":"2019","unstructured":"Boschi D, Pippione AC, Sainas S, Lolli ML. Dihydroorotate dehydrogenase inhibitors in anti-infective drug research. Eur J Med Chem. 2019;183:111681.","journal-title":"Eur J Med Chem"},{"key":"268_CR34","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1016\/j.bbmt.2019.04.028","volume":"25","author":"A Gokarn","year":"2019","unstructured":"Gokarn A, Toshniwal A, Pathak A, Arora S, Bonda A, Punatar S, et al. Use of leflunomide for treatment of cytomegalovirus infection in recipients of allogeneic stem cell transplant. Biol Blood Marrow Transplant. 2019;25:1832\u20136.","journal-title":"Biol Blood Marrow Transplant"},{"key":"268_CR35","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1399-3062.2006.00128.x","volume":"8","author":"ME Levi","year":"2006","unstructured":"Levi ME, Mandava N, Chan LK, Weinberg A, Olson JL. Treatment of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide. Transpl Infect Dis. 2006;8:38\u201343.","journal-title":"Transpl Infect Dis"},{"key":"268_CR36","doi-asserted-by":"publisher","first-page":"637","DOI":"10.2217\/imt.10.52","volume":"2","author":"S Teschner","year":"2010","unstructured":"Teschner S, Burst V. Leflunomide: a drug with a potential beyond rheumatology. Immunotherapy. 2010;2:637\u201350.","journal-title":"Immunotherapy"},{"key":"268_CR37","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/0-387-32957-9_18","volume":"577","author":"MA Josephson","year":"2006","unstructured":"Josephson MA, Javaid B, Kadambi PV, Meehan SM, Williams JW. Leflunomide in solid organ transplantation and polyoma virus infection. Adv Exp Med Biol. 2006;577:255\u201365.","journal-title":"Adv Exp Med Biol"},{"key":"268_CR38","doi-asserted-by":"publisher","first-page":"e13176","DOI":"10.1111\/ctr.13176","volume":"32","author":"JT Silva","year":"2018","unstructured":"Silva JT, Perez-Gonzalez V, Lopez-Medrano F, Alonso-Moralejo R, Fernandez-Ruiz M, San-Juan R, et al. Experience with leflunomide as treatment and as secondary prophylaxis for cytomegalovirus infection in lung transplant recipients: a case series and review of the literature. Clin Transplant. 2018;32:e13176.","journal-title":"Clin Transplant"},{"key":"268_CR39","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s12250-020-00258-7","volume":"35","author":"K Hu","year":"2020","unstructured":"Hu K, Wang M, Zhao Y, Zhang Y, Wang T, Zheng Z, et al. A small-scale medication of leflunomide as a treatment of covid-19 in an open-label blank-controlled clinical trial. Virol Sin. 2020;35:725\u201333.","journal-title":"Virol Sin"},{"key":"268_CR40","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12985-020-01339-5","volume":"17","author":"J Ruan","year":"2020","unstructured":"Ruan J, Sun S, Cheng X, Han P, Zhang Y, Sun D. Mitomycin, 5-fluorouracil, leflunomide, and mycophenolic acid directly promote hepatitis b virus replication and expression in vitro. Virol J. 2020;17:89.","journal-title":"Virol J"},{"key":"268_CR41","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1136\/annrheumdis-2020-219498","volume":"80","author":"A Strangfeld","year":"2021","unstructured":"Strangfeld A, Schafer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, et al. Factors associated with covid-19-related death in people with rheumatic diseases: results from the covid-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis. 2021;80:930\u201342.","journal-title":"Ann Rheum Dis"},{"issue":"481\u201391","key":"268_CR42","volume":"159","author":"EJ Brenner","year":"2020","unstructured":"Brenner EJ, Ungaro RC, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, et al. Corticosteroids, but not tnf antagonists, are associated with adverse covid-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology. 2020;159(481\u201391): e3.","journal-title":"Gastroenterology"},{"key":"268_CR43","doi-asserted-by":"publisher","first-page":"4476","DOI":"10.3390\/ijms20184476","volume":"20","author":"MG Feria-Garz\u00f3n","year":"2019","unstructured":"Feria-Garz\u00f3n MG, Rugeles MT, Hernandez JC, Lujan JA, Taborda NA. Sulfasalazine as an immunomodulator of the inflammatory process during HIV-1 infection. Int J Mol Sci. 2019;20:4476.","journal-title":"Int J Mol Sci"},{"key":"268_CR44","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00296-020-04771-6","volume":"41","author":"WH Bos","year":"2021","unstructured":"Bos WH, van Tubergen A, Vonkeman HE. Telemedicine for patients with rheumatic and musculoskeletal diseases during the covid-19 pandemic; a positive experience in the Netherlands. Rheumatol Int. 2021;41:565\u201373.","journal-title":"Rheumatol Int"},{"key":"268_CR45","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.semarthrit.2017.03.014","volume":"47","author":"M Piga","year":"2017","unstructured":"Piga M, Cangemi I, Mathieu A, Cauli A. Telemedicine for patients with rheumatic diseases: systematic review and proposal for research agenda. Semin Arthritis Rheum. 2017;47:121\u20138.","journal-title":"Semin Arthritis Rheum"},{"key":"268_CR46","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1136\/annrheumdis-2020-217717","volume":"79","author":"E Bozzalla Cassione","year":"2020","unstructured":"Bozzalla Cassione E, Zanframundo G, Biglia A, Codullo V, Montecucco C, Cavagna L. Covid-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine. Ann Rheum Dis. 2020;79:1382\u20133.","journal-title":"Ann Rheum Dis"},{"key":"268_CR47","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217548","volume":"80","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Wang J, Zhao L, Xiao J, Shi Z. Online management of rheumatoid arthritis during covid-19 pandemic. Ann Rheum Dis. 2021;80: e4.","journal-title":"Ann Rheum Dis"},{"key":"268_CR48","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/jso.26327","volume":"123","author":"M Sonagli","year":"2021","unstructured":"Sonagli M, Cagnacci Neto R, Leite FPM, Makdissi FBA. The use of telemedicine to maintain breast cancer follow-up and surveillance during the covid-19 pandemic. J Surg Oncol. 2021;123:371\u20134.","journal-title":"J Surg Oncol"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-022-00268-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42358-022-00268-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-022-00268-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T05:22:46Z","timestamp":1669180966000},"score":1,"resource":{"primary":{"URL":"https:\/\/advancesinrheumatology.biomedcentral.com\/articles\/10.1186\/s42358-022-00268-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,22]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["268"],"URL":"https:\/\/doi.org\/10.1186\/s42358-022-00268-x","relation":{},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,22]]},"assertion":[{"value":"8 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was registered at the Brazilian Registry of Clinical Trials \u2013 REBEC, RBR-33YTQC. This study was approved by the National Research Ethics Commission (CONEP), approval number 3,955,206, of April 5, 2020, and all patients read and signed the informed consent form before inclusion, including consent for anonymous data publication, in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"All patients gave a consent for anonymous data publication, in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45"}}